natgillin/translations-raw huggingface dataset:
Dosisreduktion af alfentanil og andre korttidsvirkende opiater, der har samme struktur som alfentanil, og som metaboliseres af CYP3A4 (f. eks. fentanyl og sufentanil) bør overvejes ved samtidig administration af voriconazol (se pkt.
Reduction in the dose of alfentanil and other short acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e. g. fentanyl and sufentanil) should be considered when co-administered with voriconazole (see section 4.5).
Det kan derfor være nødvendigt med en længere overvågning af respirationen.
As the half-life of alfentanil is prolonged in a four-fold manner when alfentanil is coadministered with voriconazole, a longer respiratory monitoring period may be necessary.
Ritonavir (potent CYP450- induktor; CYP3A4- hæmmer og - substrat):
Ritonavir (potent CYP450 inducer; CYP3A4 inhibitor and substrate):
4. 3).
Coadministration of voriconazole and low dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/ risk justifies the use of voriconazole (see section 4.5, for higher doses see section 4.3).
Efavirenz (CYP450- induktor; CYP3A4- hæmmer og - substrat):
Efavirenz (CYP450 inducer; CYP3A4 inhibitor and substrate):
4. 2 og 4. 5).
When voriconazole is coadministered with efavirenz the dose of voriconazole should be increased to 400 mg every 12 hours and that of efavirenz should be decreased to 300 mg every 24 hours (see sections 4.2 and 4.5.).
VFEND tabletter indeholder lactose, og bør ikke gives til patienter med sjældne arvelige problemer med galactoseintolerans, Lapp lactasemangel eller glucose- galactosemalabsorption.
VFEND tablets contain lactose and should not be given to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Medmindre andet er specificeret, er lægemiddelinteraktionsstudierne udført hos raske voksne mandlige forsøgspersoner ved anvendelse af oral voriconazol på 200 mg 2 gange dagligt indtil steady state.
Unless otherwise specified, drug interaction studies have been performed in healthy adult male subjects using multiple dosing to steady state with oral voriconazole at 200 mg twice daily.
Dette afsnit omfatter andre lægemidlers virkning på voriconazol, virkninger af voriconazol på andre lægemidler og to- vejs interaktioner.
6 This section addresses the effects of other medicinal products on voriconazole, the effects of voriconazole on other medicinal products and two-way interactions.
Kontraindikationer, interaktioner der kræver dosisjustering og omhyggelig klinisk og/ eller 6 biologisk monitorering, og til sidst dem der ingen signifikant farmakokinetisk interaktion har, men som har klinisk interesse for det terapeutiske område.
The interactions for the first two sections are presented in the following order: contraindications, those requiring dosage adjustment and careful clinical and/ or biological monitoring and finally those that have no significant pharmacokinetic interaction but may be of clinical interest in this therapeutic field.
Voriconazol metaboliseres via cytochrom P450- isoenzymerne CYP2C19, CYP2C9 og CYP3A4.
Effects of other medicinal products on voriconazole Voriconazole is metabolised by cytochrome P450 isoenzymes, CYP2C19, CYP2C9 and CYP3A4.
Hæmmere eller induktorer af disse isoenzymer kan give henholdsvis en stigning eller et fald i voriconazol- plasmakoncentrationerne.
Inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations respectively.
Rifampicin (CYP450- induktor):
Rifampicin (CYP450 inducer):
Rifampicin (600 mg én gang dagligt) nedsætter Cmax (maksimal plasmakoncentration) og AUCτ (arealet under plasmakoncentrationstidskurven inden for et dosisinterval) af voriconazol med henholdsvis 93% og 96%.
Rifampicin (600 mg once daily) decreased the Cmax (maximum plasma concentration) and AUCτ (area under the plasma concentration time curve within a dose interval) of voriconazole by 93% and 96%, respectively.
4. 3).
Coadministration of voriconazole and rifampicin is contraindicated (see section 4.3).
Ritonavir (potent CYP450- induktor; CYP3A4- hæmmer og - subtrat):
Ritonavir (potent CYP450 inducer; CYP3A4 inhibitor and substrate):
Effekten af samtidig administration af oral voriconazol (200 mg 2 gange dagligt) og højdosis (400 mg) og lavdosis (200 mg) oral ritonavir er undersøgt i 2 separate studier af raske frivillige forsøgspersoner.
The effect of the coadministration of oral voriconazole (200 mg twice daily) and high dose (400 mg) and low dose (100 mg) oral ritonavir was investigated in two separate studies in healthy volunteers.
Høje doser af ritonavir (400 mg 2 gange dagligt) nedsætter steady state Cmax og AUCτ af oral voriconazol med gennemsnitlig henholdsvis 66% og 82%, mens lave doser af ritonavir (100 mg 2 gange dagligt) nedsætter steady state Cmax og AUCτ af voriconazol med gennemsnitlig henholdsvis 24% og 39%.
High doses of ritonavir (400 mg twice daily) decreased the steady state Cmax and AUCτ of oral voriconazole by an average of 66% and 82%, whereas low doses of ritonavir (100 mg twice daily) decreased the Cmax and AUCτ of voriconazole by an average of 24% and 39% respectively.
Administration af voriconazol har ingen signifikant effekt på middel Cmax og AUCτ af ritonavir i højdosis- studiet, men der ses en lille nedsættelse af steady state Cmax og AUCτ af ritonavir med gennemsnitlig henholdsvis 25% og 13% i lavdosis ritonavir interaktionsstudiet.
Administration of voriconazole did not have a significant effect on mean Cmax and AUCτ of ritonavir in the high dose study, although a minor decrease in steady state Cmax and AUCτ of ritonavir with an average of 25% and 13% respectively was observed in the low dose ritonavir interaction study.
I hvert af ritonavir interaktionsstudierne blev en patient (outlier) identificeret med forhøjet voriconazol- niveau.
One outlier subject with raised voriconazole levels was identified in each of the ritonavir interaction studies.
Samtidig administration af voriconazol og høje doser ritonavir (400 mg og derover 2 gange dagligt) er kontraindiceret.
Coadministration of voriconazole and high doses of ritonavir (400 mg and above twice daily) is contraindicated.
4. 3 og 4. 4).
Coadministration of voriconazole and low dose ritonavir (100 mg twice daily) should be avoided, unless an assessment of the benefit/ risk to the patient justifies the use of voriconazole (see section 4.3 and 4.4).
Carbamazepin og phenobarbital (potente CYP450- induktorer):
Carbamazepine and phenobarbital (potent CYP450 inducers):
Skønt det ikke er undersøgt, er det sandsynligt, at carbamazepin eller phenobarbital vil nedsætte voriconazol- plasmakoncentrationerne signifikant.
Although not studied, carbamazepine or phenobarbital are likely to significantly decrease plasma voriconazole concentrations.
4. 3).
Coadministration of voriconazole with carbamazepine and phenobarbital is contraindicated (see section 4.3).
Cimetidin (non- specifik CYP450- hæmmer, øger gastrisk pH):
Cimetidine (non-specific CYP450 inhibitor and increases gastric pH):
Cimetidin (400 mg 2 gange dagligt) øger voriconazols Cmax og AUCτ med henholdsvis 18% og 23%.
Cimetidine (400 mg twice daily) increased voriconazole Cmax and AUCτ by 18% and 23%, respectively.
Dosisjustering af voriconazol er ikke nødvendig.
No dosage adjustment of voriconazole is recommended.
Ranitidin (øger gastrisk pH):
Ranitidine (increases gastric pH):
Ranitidin (150 mg 2 gange dagligt) har ingen signifikant effekt på voriconazols Cmax og AUCτ.
Ranitidine (150 mg twice daily) had no significant effect on voriconazole Cmax and AUCτ.
Makrolid- antibiotika:
Macrolide antibiotics:
Erythromycin (CYP3A4- hæmmer; 1g 2 gange dagligt) og azithromycin (500 mg én gang dagligt) har ingen signifikant effekt på voriconazols Cmax og AUCτ.
Erythromycin (CYP3A4 inhibitor; 1 g twice daily) and azithromycin (500 mg once daily) had no significant effect on voriconazole Cmax and AUCτ.
Perikon (CYP450- induktor; P- gp- induktor):
St John’ s Wort (CYP450 inducer; P-gp inducer):
I et klinisk forsøg med raske frivillige forsøgspersoner udviste perikon initialt en kortvarig, hæmmende effekt efterfulgt af induktion af voriconazol - metabolismen.
In a clinical study in healthy volunteers, St John’ s Wort exhibited a short initial inhibitory effect followed by induction of voriconazole metabolism.
Efter 15 dages behandling med perikon (300 mg 3 gange dagligt) faldt plasmaeksponeringen med 40- 60% efter en enkeltdosis på 400 mg voriconazol.
After 15 days of treatment with St John’ s Wort (300 mg three times daily), plasma exposure following a single 400 mg dose of voriconazole decreased by 40-60%.
4. 3).
Therefore, concomitant use of voriconazole with St John’ s Wort is contraindicated (see section 4.3).
Voriconazol hæmmer aktiviteten af cytochrom P450- isoenzymerne CYP2C19, CYP2C9 og CYP3A4.
Effects of voriconazole on other medicinal products Voriconazole inhibits the activity of cytochrome P450 isoenzymes, CYP2C19, CYP2C9 and CYP3A4.
Derfor er der potentiale for, at voriconazol øger plasmaniveauerne for stoffer, der metaboliseres af disse CYP450- isoenzymer.
Therefore there is potential for voriconazole to increase the plasma levels of substances metabolised by these CYP450 isoenzymes.
7 Voriconazol bør anvendes med forsigtighed hos patienter, der samtidig tager medicin, som er kendt for at forlænge QT- intervallet.
7 Voriconazole should be administered with caution in patients with concomitant medication that is known to prolong QT interval.
4. 3).
When there is also a potential for voriconazole to increase the plasma levels of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, cisapride, pimozide) co-administration is contraindicated (see below and section 4.3).
Terfenadin, astemizol, cisaprid, pimozid og quinidin (CYP3A4- substrater):
Terfenadine, astemizole, cisapride, pimozide and quinidine (CYP3A4 substrates):
4. 3).
Although not studied, coadministration of voriconazole with terfenadine, astemizole, cisapride, pimozide, or quinidine is contraindicated, since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes (see section 4.3).
Sirolimus (CYP3A4- substrat):
Sirolimus (CYP3A4 substrate):
Voriconazol øger Cmax og AUCτ af sirolimus (2 mg enkeltdosis) med henholdsvis 556% og 1014%.
Voriconazole increased sirolimus (2 mg single dose) Cmax and AUCτ by 556% and 1014%, respectively.
4. 3).
Coadministration of voriconazole and sirolimus is contraindicated (see section 4.3).
Sekalealkoloider (CYP3A4- substrater):
Ergot alkaloids (CYP3A4 substrates):
Skønt det ikke er undersøgt, kan voriconazol muligvis øge plasmakoncentrationer af sekalealkaloider (ergotamin og dihydroergotamin) og medføre ergotisme.
Although not studied, voriconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) and lead to ergotism.
4. 3).
Coadministration of voriconazole with ergot alkaloids is contraindicated (see section 4.3).
Ciclosporin (CYP3A4- substrat):
Ciclosporin (CYP3A4 substrate):
Hos stabile nyretransplanterede øger voriconazol ciclosporins Cmax og AUCτ med henholdsvis mindst 13% og 70%.
In stable, renal transplant recipients, voriconazole increased ciclosporin Cmax and AUCτ by at least 13% and 70% respectively.
Når voriconazol initieres hos patienter, der allerede får ciclosporin, anbefales det, at ciclosporindosis halveres, og at ciclosporinniveauet monitoreres omhyggeligt.
When initiating voriconazole in patients already receiving ciclosporin it is recommended that the ciclosporin dose be halved and ciclosporin level carefully monitored.
Stigning i ciclosporinniveauer har været forbundet med nefrotoksicitet.
Increased ciclosporin levels have been associated with nephrotoxicity.
Når voriconazolbehandling afbrydes, skal ciclosporinniveauerne omhyggeligt monitoreres, og dosis af ciclosporin øges efter behov.
When voriconazole is discontinued, ciclosporin levels must be carefully monitored and the dose increased as necessary.
65% og 103%.
In subjects receiving a methadone maintenance dose (32-100 mg once daily) coadministration of oral voriconazole (400 mg twice daily for 1 day, then 200 mg twice daily for four days) increased the Cmax and AUC of pharmacologically active R-methadone by 31% and 47%, respectively, whereas the Cmax and AUC of the S-enantiomer increased by approximately 65% and 103%, respectively.
Ved samtidig administration af methadon er voriconazols plasmakoncentrationer sammenlignelige med voriconazolniveauerne (historiske data) hos raske forsøgspersoner uden nogen samtidig administration.
Voriconazole plasma concentrations during coadministration of methadone were comparable to voriconazole levels (historical data) in healthy subjects without any comedication.
Ved samtidig administration af voriconazol anbefales der hyppig monitorering af bivirkninger og toksicitet i forbindelse med øgede plasmakoncentrationer af methadon, herunder QT- forlængelse, da methadonniveauer stiger efter samtidig administration.
Frequent monitoring for adverse events and toxicity related to increased plasma concentrations of methadone, including QT prolongation, is recommended during coadministration.
Steady state administration af oral voriconazol øger AUCτ af en enkeltdosis alfentanil 6 gange.
Steady-state administration of oral voriconazole increased the AUCτ of a single dose of alfentanil by 6-fold.
4. 4).
Reduction in the dose of alfentanil and other short acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e. g. fentanyl and sufentanil), should be considered when coadministered with voriconazole (see section 4.4).
Tacrolimus (CYP3A4- substrat):
Tacrolimus (CYP3A4 substrate):
Voriconazol øger Cmax og AUCt (arealet under plasmakoncentrationtidskurven til den sidst kvantificerbare måling) af tacrolimus (0, 1 mg/ kg enkeltdosis) med henholdsvis 117% og 221%.
Voriconazole increased tacrolimus (0.1 mg/ kg single dose) Cmax and AUCt (area under the plasma concentration time curve to the last quantifiable measurement) by 117% and 221%, respectively.
Når voriconazol initieres hos patienter, der allerede får tacrolimus, anbefales det, at tacrolimusdosis nedsættes til en tredjedel af den oprindelige dosis, og at tacrolimusniveauet monitoreres omhyggeligt.
When initiating voriconazole in patients already receiving tacrolimus, it is recommended that the tacrolimus dose be reduced to a third of the original dose and tacrolimus level carefully monitored.
Stigning i tacrolimusniveauer har været forbundet med nefrotoksicitet.
Increased tacrolimus levels have been associated with nephrotoxicity.
Når voriconazolbehandling afbrydes, skal tacrolimusniveauerne omhyggeligt monitoreres, og dosis af tacrolimus øges efter behov.
When voriconazole is discontinued, tacrolimus levels must be carefully monitored and the dose increased as necessary.
Orale antikoagulantia:
Oral anticoagulants:
Warfarin (CYP2C9- substrat):
Warfarin (CYP2C9 substrate):
Samtidig administration af voriconazol (300 mg 2 gange dagligt) og warfarin (30 mg enkeltdosis) øger maksimum protrombintid med 93%.
Coadministration of voriconazole (300 mg twice daily) with warfarin (30 mg single dose) increased maximum prothrombin time by 93%.
Nøje monitorering af protrombintiden anbefales, hvis warfarin gives samtidigt med voriconazol.
Close monitoring of prothrombin time is recommended if warfarin and voriconazole are coadministered.
8 Andre orale antikoagulantia, f. eks. phenprocoumon, acenocoumarol (CYP2C9, CYP3A4- substrater):
8 Other oral anticoagulants e. g. phenprocoumon, acenocoumarol (CYP2C9, CYP3A4 substrates):
Skønt det ikke er undersøgt, kan voriconazol muligvis øge plasmakoncentrationer af coumariner, og dermed føre til øget protrombintid.
Although not studied, voriconazole may increase the plasma concentrations of coumarins and therefore may cause an increase in prothrombin time.
Patienter, der får coumariner og voriconazol samtidig, bør have monitoreret protrombintiden med korte intervaller, og dosis af antikoagulantia bør tilsvarende justeres.
If patients receiving coumarin preparations are treated simultaneously with voriconazole, the prothrombin time should be monitored at close intervals and the dosage of anticoagulants adjusted accordingly.
Sulfonylurinstoffer (CYP2C9- substrater):
Sulphonylureas (CYP2C9 substrates):
Skønt det ikke er undersøgt, kan voriconazol give en stigning i sulfonylurinstoffernes plasmaniveauer (f. eks. tolbutamid, glipizid og glyburid) og derfor forårsage hypoglykæmi.
Although not studied, voriconazole may increase the plasma levels of sulphonylureas (e. g. tolbutamide, glipizide, and glyburide) and therefore cause hypoglycaemia.
Ved samtidig administration anbefales omhyggelig monitorering af blodsukkeret.
Careful monitoring of blood glucose is recommended during coadministration.
Statiner (CYP3A4- substrater):
Statins (CYP3A4 substrates):
Skønt det ikke er klinisk undersøgt, har voriconazol vist at hæmme lovastatins metabolisme in vitro (humane levermikrosomer).
Although not studied clinically, voriconazole has been shown to inhibit lovastatin metabolism in vitro (human liver microsomes).
Derfor skønnes det, at voriconazol kan øge plasmaniveauer af statiner, der metaboliseres af CYP3A4.
Therefore, voriconazole is likely to increase plasma levels of statins that are metabolised by CYP3A4.
Ved samtidig administration anbefales det at overveje en dosisjustering af statinerne.
It is recommended that dose adjustment of the statin be considered during coadministration.
En stigning i statinniveauerne har været associeret med rhabdomyolyse.
Increased statin levels have been associated with rhabdomyolysis.
Benzodiazepiner (CYP3A4- substrater):
Benzodiazepines (CYP3A4 substrates):
Skønt det ikke er klinisk undersøgt, har voriconazol vist at hæmme midazolams metabolisme in vitro (humane levermikrosomer).
Although not studied clinically, voriconazole has been shown to inhibit midazolam metabolism in vitro (human liver microsomes).
Derfor skønnes det, at voriconazol kan øge benzodiazepinernes plasmaniveauer, som er metaboliseret af CYP3A4 (midazolam og triazolam) og føre til en forlænget sedativ effekt.
Therefore, voriconazole is likely to increase the plasma levels of benzodiazepines that are metabolised by CYP3A4 (midazolam and triazolam) and lead to a prolonged sedative effect.
Ved samtidig administration anbefales det at overveje en dosisjustering af benzodiazepinerne.
It is recommended that dose adjustment of the benzodiazepine be considered during coadministration.
Vinkaalkaloider (CYP3A4 substrater):
Vinca Alkaloids (CYP3A4 substrates):
Skønt det ikke er undersøgt, kan voriconazol give en stigning i vinkaalkaloidernes plasmaniveauer (f. eks. vincristin og vinblastin) og føre til neurotoksicitet.
Although not studied, voriconazole may increase the plasma levels of the vinca alkaloids (e. g. vincristine and vinblastine) and lead to neurotoxicity.
Prednisolon (CYP3A4- substrat):
Prednisolone (CYP3A4 substrate):
Voriconazol øger Cmax og AUCτ af prednisolon (60 mg enkeltdosis) med henholdsvis 11% og 34%.
Voriconazole increased Cmax and AUCτ of prednisolone (60 mg single dose) by 11% and 34%, respectively.
Dosisjustering er ikke nødvendig.
No dosage adjustment is recommended.
Digoxin (P- glycoprotein- medieret transport):
Digoxin (P-glycoprotein mediated transport):
Voriconazol har ingen signifikant effekt på Cmax og AUCτ af digoxin (0, 25 mg én gang dagligt).
Voriconazole had no significant effect on Cmax and AUCτ of digoxin (0.25 mg once daily).
Mycophenolsyre (UDP- glucuronyltransferasesubstrat):
Mycophenolic acid (UDP-glucuronyl transferase substrate):
Voriconazol har ingen effekt på Cmax og AUCτ mycophenolsyre (1 g enkeltdosis).
Voriconazole had no effect on the Cmax and AUCt of mycophenolic acid (1 g single dose).
Nonsteroide antiinflamatoriske lægemidler (CYP2C9- substrater):
Non-Steroidal Anti-Inflammatory Drugs (CYP2C9 substrates):
Voriconazol øger Cmax og AUC af ibuprofen (400 mg enkeltdosis) med henholdsvis 20% og 100%.
Voriconazole increased Cmax and AUC of ibuprofen (400 mg single dose) by 20% and 100%, respectively.
Voriconazol øger Cmax og AUC af diclofenac (50 mg enkeltdosis) med henholdsvis 114% og 78%.
Voriconazole increased Cmax and AUC of diclofenac (50 mg single dose) by 114% and 78%, respectively.
Der anbefales regelmæssig kontrol af bivirkninger og toksicitet, der er relateret til NSAID.
Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended.
Det kan være nødvendigt at justere dosis af NSAID.
Adjustment of dosage of NSAIDs may be needed.
To- vejs interaktioner
Two-way interactions
Samtidig behandling med voriconazol og phenytoin bør undgås, medmindre fordelen opvejer risikoen.
Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk.
Phenytoin (300 mg én gang dagligt) giver et fald i voriconazols Cmax og AUCτ på henholdsvis 49% og 69%.
Phenytoin (300 mg once daily) decreased the Cmax and AUCτ of voriconazole by 49% and 69%, respectively.
4. 2) giver en stigning i Cmax og AUCτ af phenytoin (300 mg én gang dagligt) på henholdsvis 67% og 81%.
Voriconazole (400 mg twice daily, see section 4.2) increased Cmax and AUCτ of phenytoin (300 mg once daily) by 67% and 81%, respectively.
Der anbefales omhyggelig monitorering af plasmaphenytoinniveauerne, når phenytoin administreres samtidigt med voriconazol.
Careful monitoring of phenytoin plasma levels is recommended when phenytoin is coadministered with voriconazole.
4. 2.
Phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 5 mg/ kg intravenously twice daily or from 200 mg to 400 mg orally, twice daily (100 mg to 200 mg orally, twice daily in patients less than 40 kg), see section 4.2.
Samtidig behandling med voriconazol og rifabutin bør undgås, medmindre fordelen opvejer risikoen.
Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk.
9 Rifabutin (300 mg én gang dagligt) nedsatte Cmax og AUCτ af voriconazol 200 mg 2 gange dagligt med henholdsvis 69% og 78%.
Rifabutin (300 mg once daily) decreased the Cmax and AUCτ of voriconazole at 200 mg twice daily by 69% and 78%, respectively.
Ved samtidig administration af rifabutin var Cmax og AUCτ af voriconazol 350 mg 2 gange dagligt 96% og 68% af de niveauer, der blev set, hvis der blev givet voriconazol 200 mg 2 gange dagligt alene.
9 rifabutin, the Cmax and AUCτ of voriconazole at 350 mg twice daily were 96% and 68% of the levels when administered alone at 200 mg twice daily.
Ved en dosis af voriconazol på 400 mg 2 gange dagligt var Cmax og AUCτ henholdsvis 104% og 87% højere sammenlignet med voriconazol 200 mg 2 gange dagligt alene.
At a voriconazole dose of 400 mg twice daily Cmax and AUCτ were 104% and 87% higher, respectively, compared with voriconazole alone at 200 mg twice daily.
Ved voriconazol 400 mg 2 gange dagligt steg Cmax og AUCτ af rifabutin med henholdsvis 195% og 331%.
Voriconazole at 400 mg twice daily increased Cmax and AUCτ of rifabutin by 195% and 331%, respectively.
4. 2).
If rifabutin coadministration with voriconazole is justified then the maintenance dose of voriconazole may be increased to 5 mg/ kg intravenously twice daily or from 200 mg to 350 mg orally, twice daily (100 mg to 200 mg orally, twice daily in patients less than 40 kg) (see section 4.2).
Omhyggelig monitorering af fuldt blodbillede og bivirkninger til rifabutin (f. eks. uveitis) anbefales, hvis rifabutin gives samtidig med voriconazol.
Careful monitoring of full blood counts and adverse events to rifabutin (e. g. uveitis) is recommended when rifabutin is coadministered with voriconazole.
Omeprazol (CYP2C19- hæmmer; CYP2C19 og CYP3A4- substrat):
Omeprazole (CYP2C19 inhibitor; CYP2C19 and CYP3A4 substrate):
Omeprazol (40 mg én gang dagligt) øger voriconazols Cmax og AUCτ med henholdsvis 15% og 41%.
Omeprazole (40 mg once daily) increased voriconazole Cmax and AUCτ by 15% and 41%, respectively.
Voriconazol øger omeprazols Cmax og AUCτ med henholdsvis 116% og 280%.
Voriconazole increased omeprazole Cmax and AUCτ by 116% and 280%, respectively.